Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095225
Status:
COMPLETED
Last Update Posted:
2008-01-29
First Post:
2004-11-01
Brief Title:
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC Non-Small Cell Lung Cancer
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase II Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Docetaxel or Pemetrexed or Tarceva Erlotinib Compared With Chemotherapy Docetaxel or Pemetrexed Alone for Treatment of Recurrent or Refractory Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase II multicenter randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy docetaxel or pemetrexed or Tarceva relative to chemotherapy docetaxel or pemetrexed alone in patients with previously treated advanced NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None